secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001213900-24-096269
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports 27% ORR, 33% CBR in Phase I trial of LYMPHIR + pembrolizumab for recurrent solid tumors
--------------------------------------------------------------------------------

- 27% objective response rate (4/15 evaluable) and 33% clinical benefit rate (5/15) in heavily pre-treated gynecologic tumors.
- Median progression-free survival of 57 weeks (range 30-96 weeks) for patients achieving clinical benefit.
- Combination was well-tolerated with no documented ≥Grade 3 immune-related adverse events; one dose-limiting toxicity (capillary leak) at 12 mcg/kg.
- Two of four partial responders had failed prior anti-PD-1 therapy, suggesting potential to overcome checkpoint resistance.
- Trial nearing completion with three additional patients to enroll; data presented at SITC 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/0001213900-24-096269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea0220666-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-096269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer